Trastuzumab combined with irinotecan in patients with HER2-positive metastatic colorectal cancer: A phase II single-arm study and exploratory biomarker analysis

医学 曲妥珠单抗 内科学 伊立替康 肿瘤科 结直肠癌 临床终点 克拉斯 帕妥珠单抗 癌症 中性粒细胞减少症 乳腺癌 化疗 临床试验
作者
Ting Xu,Xicheng Wang,Ying Xin,Zhenghang Wang,Jifang Gong,Xiaotian Zhang,Yanyan Li,Congcong Ji,Yu Sun,Feilong Zhao,Depei Huang,Yuezong Bai,Jian Li,Lin Shen
出处
期刊:Cancer Research and Treatment [Korean Cancer Association]
被引量:1
标识
DOI:10.4143/crt.2022.1058
摘要

The human epidermal growth factor receptor 2 (HER2) is an established therapeutic target for various kinds of solid tumors. HER2 amplification occurs in approximately 1% to 6% of colorectal cancer. In this study, we aimed to assess the efficacy and safety of trastuzumab in combination with chemotherapy in HER2-positive mCRC.An open-label, phase II trial (Clinicaltrials.gov: NCT03185988) was designed to evaluate the antitumor activity of trastuzumab and chemotherapy in HER2-positive digestive cancers excluding gastric cancer in 2017. Patients from this trial with HER2-positive, KRAS/BRAF wild-type, unresectable mCRC were analyzed in this manuscript. Eligible patients were treated with trastuzumab (8 mg/kg loading dose and then 6 mg/kg q3w) and irinotecan (120 mg/m2 d1,8 q3w). The primary endpoint was the objective response rate (ORR).Twenty-one HER2-positive mCRC patients were enrolled in this study. Seven (33.3%) patients achieved an objective response, and 11 (52.4%) patients had stable disease as their best response. The median progression-free survival (PFS) was 4.3 months (95% CI: 2.7 - 5.9 m). Four (19.0%) of the 21 patients had Grade 3 adverse events, including leukopenia, neutropenia, urinary tract infection, and diarrhea. No treatment-related death was reported. Exploratory analyses revealed that high tumor tissue HER2 copy number was associated with better therapeutic response and PFS. Alterations in the MAPK pathway, HER2 gene, PI3k/AKT pathway, and cell cycle control genes were potential drivers of trastuzumab resistance in mCRC.Trastuzumab combined with chemotherapy is a potentially effective and well-tolerated therapeutic regimen in mCRC with a high HER2 copy number.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
华仔的应助被geold采纳,获得10
刚刚
MJQ完成签到,获得积分10
1秒前
南辞完成签到 ,获得积分10
2秒前
ZsJJkk发布了新的文献求助10
2秒前
阿飞发布了新的文献求助10
2秒前
打打的应助被米米采纳,获得10
2秒前
123zyuyu完成签到,获得积分10
2秒前
可爱眼神完成签到,获得积分20
2秒前
尘_完成签到,获得积分10
2秒前
2秒前
3秒前
月亮糕手完成签到,获得积分10
3秒前
3秒前
ROSEANNE完成签到,获得积分10
3秒前
leezh完成签到,获得积分10
3秒前
涛涛完成签到,获得积分10
4秒前
潆星完成签到,获得积分10
4秒前
LEETHEO发布了新的文献求助10
4秒前
淳简菈基茨德完成签到 ,获得积分10
4秒前
大胆书南完成签到,获得积分10
4秒前
4秒前
领导范儿的应助被Overtone采纳,获得10
5秒前
坚强抽屉发布了新的文献求助10
5秒前
钟贵泉完成签到,获得积分10
5秒前
甜美的瑾瑜完成签到,获得积分10
5秒前
标致青雪发布了新的文献求助10
5秒前
zyy完成签到,获得积分20
5秒前
小晨同学完成签到 ,获得积分10
6秒前
多发论文早毕业完成签到,获得积分10
6秒前
余杭村王小虎完成签到,获得积分10
6秒前
Lyuhng+1发布了新的文献求助10
6秒前
6秒前
陈小白完成签到,获得积分10
7秒前
7秒前
7秒前
月亮完成签到,获得积分10
7秒前
8秒前
8秒前
8秒前
科研通AI6.3的应助被hjy采纳,获得10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180586
求助须知:如何正确求助?哪些是违规求助? 9570581
关于积分的说明 21813457
捐赠科研通 7776777
什么是DOI,文献DOI怎么找? 3433294
关于科研通互助平台的介绍 2557547
邀请新用户注册赠送积分活动 2479253